Smarter leaders trust GlobalData

Data Insights Innovation in pharma: T-cell binding fusion peptides

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

F. Hoffmann-La Roche Ltd

Bristol-Myers Squibb Co

Fujifilm Holdings Corp

Fate Therapeutics Inc

Precision Biosciences Inc

View all

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 730,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multi-specific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Peptide pharmacophores, antibody-drug conjugates and neuroprotective drugs are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are amyloid precursor targeted therapies and modified vector HIV-1 vaccines, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

T-cell binding fusion peptides is a key innovation area in the pharmaceutical industry

T-cell binding fusion peptides are a type of synthetic or engineered peptide that are designed to interact with T cells, a type of immune cell involved in the adaptive immune response. T-cell binding fusion peptides are composed of amino acids, just like natural proteins and peptides. They are often engineered to include sequences that mimic or resemble antigens or epitopes recognized by T cells. The design may also include additional sequences or motifs that enhance binding to TCRs. These peptides are typically created to have specific binding affinity for T-cell receptors (TCRs) and are used in various applications, primarily in the field of immunotherapy and vaccine development.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 130+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of T-cell binding fusion peptides.

Key players in T-cell binding fusion peptides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to T-cell binding fusion peptides

Immatics is one of the leading patent filers in T-cell binding fusion peptides. Immatics is a clinical-stage biopharmaceutical company that specializes in the development of innovative immunotherapies for the treatment of cancer. The company's focus is on harnessing the power of the immune system, particularly T cells, to target and eliminate cancer cells. Immatics is known for its focus on T-cell receptor (TCR) therapies, cancer vaccines, and other immunotherapeutic approaches. Bristol-Myers Squibb (BMS) and Fate Therapeutics are some of the other key patent filers in T-cell binding fusion peptides.

In terms of application diversity, Fujifilm leads the pack, while Provincial Health Services Authority and Applied DNA Sciences stood in second and third positions, respectively.

By means of geographic reach, Immatics held the top position followed by F. Hoffmann-La Roche and Intellia Therapeutics.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.